The Effect and Safety of 5-HT_1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis

Table 4

RRs and 95% CI for the most common TEAEs during the evaluation period after the first dose.

Comparisons	Dizziness			Paresthesia			Fatigue			Somnolence			Nausea
		RR (95% CI)			RR (95% CI)			RR (95% CI)			RR (95% CI)			RR (95% CI)
Placebo comparisons
Lasmiditan 50 mg vs. placebo	3	3.54 (1.22, 10.23)	64%	3	3.35 (1.59, 7.04)	45%	3	3.05 (1.58, 5.87)	0%	2	2.86 (1.60, 5.09)	0%	2	8.38 (1.55, 45.39)	0%
Lasmiditan 100 mg vs. placebo	3	5.96 (2.77, 12.79)	69%	3	3.90 (2.43, 6.26)	21%	3	6.99 (3.62, 13.48)	0%	3	2.59 (1.70, 3.95)	0%	3	4.15 (0.82, 21.00)	60%
Lasmiditan 200 mg vs. placebo	3	6.58 (3.49, 12.39)	57%	3	5.03 (3.17, 7.99)	0%	3	6.77 (3.51, 13.07)	0%	3	2.92 (1.92, 4.42)	0%	3	4.01 (1.49, 10.76)	23%
Dosage comparisons
Lasmiditan 50 mg vs. 100 mg	2	0.63 (0.33, 1.18)	77%	2	0.38 (0.22, 0.65)	0%	2	0.64 (0.40, 1.01)	0%	2	1.08 (0.71, 1.64)	0%	2	0.74 (0.35, 1.54)	0%
Lasmiditan 100 mg vs. 200 mg	3	0.85 (0.67, 1.06)	40%	3	0.76 (0.57, 1.03)	0%	3	1.02 (0.74, 1.42)	0%	3	0.88 (0.65, 1.20)	0%	3	0.82 (0.36, 1.85)	60%
Lasmiditan 200 mg vs. 50 mg	2	0.50 (0.39, 0.65)	0%	2	3.15 (1.87, 5.30)	28%	2	0.58 (0.37, 0.91)	0%	2	0.83 (0.56, 1.24)	0%	2	0.78 (0.29, 2.10)	26%

(significant difference). : number of trials; RR: risk ratio; 95% CI: 95% confidence intervals.